CAS: 1553-60-2; 2-(4-Isobutylphenyl)Acetic Acid

该化合物是许多国家艾滋病数据库的特征,允许它抑制环氧气酶(COX)酶,并随后减少其合成,从而减少丙型腺素,炎症和疼痛的调节器.Ibufenac一般是口服的,以其相对快速行动为名.其致癌和炎症主要用于治疗与各种情况有关的疼痛和炎症,如关节炎等.Ibufenac的化学结构包括一个肠胃酸组,这是许多国家艾滋病数据库的特征,允许它抑制环氧素酶(COX)酶,并随后减少其合成.Ibufenac一般是口服的,并且以其相对快速的开始作用而闻名.它的致癌因包括胃肠道吸收,主要在肝脏中出现新陈代谢.尽管它在控制疼痛和炎症方面是有效的,但潜在的侧效应可能包括胃肠道肠不适,肾损伤和过敏反应,类似于其他国家艾滋病数据库.与任何药物一样,对于用户都有必要咨询保健专业人员进行适当的互动.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号60736-79-0 1-(chloromethyl... | CAS号15649-02-2 ethyl 4-isobuty... | CAS号110-91-8 吗啉 | CAS号38861-78-8 4-异丁基苯乙酮 | CAS号36039-35-7 2-(4-异丁基苯基)乙烷-1-醇 | CAS号58142-20-4 (4-isobutyl-2-o... | CAS号40150-98-9 4-异丁基苯甲醛 | CAS号4360-68-3 2-(4-Bromopheny... | CAS号4654-39-1 4-溴苯乙醇 | CAS号99-90-1 4-溴苯乙酮 | CAS号51146-56-6 (S)-(+)-布洛芬 | CAS号15687-27-1 布洛芬 | CAS号61566-33-4 methyl 2-(4-iso... | CAS号38588-43-1 2-[4-(2-methylp...

合成工艺路线路线简述

    📜1-(2,2-二溴乙烯基)-4-异丁基苯置于正丁基锂,异丙醇频哪醇硼酸酯体系中,用 四氢呋喃 用作溶剂,化学反应 3.5H,以76%的收率获得异丁芬酸
    参考文献:一锅法制备羧酸的方法
    标题:一锅法制备羧酸的方法
    摘要:本发明公开一种一锅法制备羧酸的方法,1,1‑二溴烯烃在正丁基锂作用下经过corey‑fuchs过程,再与异丙醇频哪醇硼酸酯反应,然后经过氯化氢淬灭,最后经氧化剂氧化,分离纯化即得羧酸.本发明方法为一锅法制备,操作简便,无需使用金属催化,反应所用试剂廉价易得且绿色环保,反应条件温和,底物适用性广,提供了一种快捷制备一系列含不同官能团羧酸的新途径.

    海关参考信息

    专利信息


    专利号:US-8546532-B2
    优先权日:2008-04-17
    标题:Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
    发明人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS
    权利人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS; DECLION PHARMACEUTICALS INC
    摘要:The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the treatment and diagnosis of protein conformational disorders, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use. The invention also pertains to the process of generating antibodies using the directed epitope peptide mixtures as the antigens, and antibodies generated by such process, useful in the treatment and diagnostics of the said protein conformational disorder.

    专利号:US-2025091989-A1
    优先权日:2023-09-19
    标 题 :Small molecule protein synthesis modulators
    发明人:GYGI DAVID; BAHMANYAR SOGOLE SAMI; HAMANN LAWRENCE
    权利人:INTERDICT BIO INC
    摘要:The present disclosure provides compounds of the formulae herein (e.g., Formula (I)), and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis (e.g., modulating synthesis of BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.

    专利号:US-2008287407-A1
    优先权日:2003-12-10
    标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
    发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

    专利号:US-8304409-B2
    优先权日:2002-07-03
    标 题:Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
    发明人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI
    权利人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI; NICOX SA
    摘要:The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

    专利号:US-9051302-B2
    优先权日:2008-01-15
    标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents
    发明人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN
    权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG
    摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.

    专利号:US-2013035307-A1
    优先权日:2010-01-26
    标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
    发明人:PRESTWICH GLENN D; KENNEDY THOMAS P
    权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
    摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献

    1. Gülcan, H.O., Ünlü, S., Dimoglo, A., et al. Marginally designed new profen analogues have the potential to inhibit cyclooxygenase enzymes. Arch.Pharm.Chem.Life Sci. 348, 55-61 (2015).

    合成参考文献


    摘要:Huang, Y.; Dömling, A., Science of Synthesis: Multicomponent Reactions, (2013) 1, 261.
    摘要:Oyo Yakuri. Pharmacometrics., 2(22), 1968
    摘要:Gekkan Yakuji. Pharmaceuticals Monthly., 9(1641), 1967
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知